Stockscreener 앱 받기
25.38
0.16%
-0.04
시간 외 거래:
25.93
0.55
+2.17%
전일 마감가:
$25.42
열려 있는:
$24.91
하루 거래량:
716.38K
Relative Volume:
0.26
시가총액:
$3.16B
수익:
$22.12M
순이익/손실:
$-245.15M
주가수익비율:
-6.5843
EPS:
-3.8546
순현금흐름:
$-373.40M
1주 성능:
+1.40%
1개월 성능:
-13.10%
6개월 성능:
+508.63%
1년 성능:
+480.78%
1일 변동 폭
$24.57
$25.71
1주일 범위
$24.56
$26.46
52주 변동 폭
$2.7601
$30.60
Alumis Inc Stock (ALMS) Company Profile
명칭
Alumis Inc
전화
650-231-6625
주소
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
25.38 | 3.17B | 22.12M | -245.15M | -373.40M | -3.8546 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 개시 | Raymond James | Strong Buy |
| 2026-02-25 | 개시 | Stifel | Buy |
| 2026-01-21 | 개시 | Chardan Capital Markets | Buy |
| 2025-07-25 | 개시 | Wells Fargo | Overweight |
| 2025-06-10 | 재개 | Guggenheim | Buy |
| 2025-01-30 | 개시 | Oppenheimer | Outperform |
| 2024-10-31 | 개시 | Robert W. Baird | Outperform |
| 2024-10-17 | 개시 | H.C. Wainwright | Buy |
| 2024-07-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-23 | 개시 | Guggenheim | Buy |
| 2024-07-23 | 개시 | Leerink Partners | Outperform |
| 2024-07-23 | 개시 | Morgan Stanley | Overweight |
모두보기
Alumis Inc 주식(ALMS)의 최신 뉴스
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis (ALMS) details 2025 results, envudeucitinib NDA plan and cash raise - Stock Titan
A psoriasis pill hit late-stage goals; Alumis plans U.S. filing in 2026 - Stock Titan
Alumis presents phase 3 psoriasis trial data at dermatology meeting By Investing.com - Investing.com India
**Key Clinical Data to Be Revealed Soon** Biopharmaceutical company Alumis Inc. announced that the phase III clinical trial data of its lead candidate drug Envudeucitinib for the treatment of moderate-to-severe plaque psoriasis has been selected for the "Lat - Bitget
Alumis presents phase 3 psoriasis trial data at dermatology meeting - Investing.com
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting - The Manila Times
Experimental oral psoriasis drug’s Phase 3 results to debut at skin conference - Stock Titan
Alumis (NASDAQ:ALMS) Trading Down 3.5%Here's What Happened - MarketBeat
ALMS Technical Analysis & Stock Price Forecast - Intellectia AI
Wells Fargo Initiates Coverage of Alumis (ALMS) with Overweight Recommendation - MSN
Alumis Inc. (NASDAQ:ALMS) Sees Significant Drop in Short Interest - MarketBeat
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Alumis Inc expected to post a loss of 98 cents a shareEarnings Preview - TradingView
Inflation Data: Can Alumis Inc ride the EV waveGold Moves & Low Risk Investment Opportunities - baoquankhu1.vn
Raymond James initiates coverage of Alumis (ALMS) with strong buy recommendation - MSN
Raymond James Starts ALMS (Alumis Inc. Common Stock) at Strong Buy Mar 2026 - Meyka
Alumis (NASDAQ:ALMS) Stock Price Down 6.7%Should You Sell? - MarketBeat
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Alumis (ALMS) to Release Earnings on Wednesday - MarketBeat
Assessing Alumis (ALMS) Valuation After A Strong Multi‑Month Share Price Run - Yahoo Finance
Raymond James initiates Alumis stock coverage citing psoriasis drug potential - Investing.com Nigeria
Alumis Teases TYK2 Catalysts at Leerink: Phase III Psoriasis Wins, NDA Plan and Lupus Readout Ahead - Yahoo Finance
TYK2 Validation and Expanding Indications Drive Buy Rating and $40 Price Target for Alumis - TipRanks
Certain Options of Alumis Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Phase III wins lift Alumis, Corcept shares in January - bioworld.com
Alumis to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
ALMS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Alumis Inc. (NASDAQ:ALMS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference - Yahoo Finance
ALMS SEC FilingsAlumis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Alumis Inc. (ALMS) Investor Outlook: Analyzing a Potential 29% Upside in Biotech Innovation - DirectorsTalk Interviews
Aug Retail: Is Alumis Inc gaining market sharePortfolio Return Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
This Oracle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Stifel Nicolaus Initiates Coverage on Alumis (NASDAQ:ALMS) - MarketBeat
Stifel Initiates Alumis at Buy With $44 Price Target - marketscreener.com
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Stifel initiates Alumis stock with buy rating on TYK2 potential - Investing.com Australia
Stifel initiates Alumis stock with buy rating on TYK2 potential By Investing.com - Investing.com Canada
ALMS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
A | What is Alumis Inc.'s debt-to-equity ratio2025 Macro Impact & Fast Moving Trade Plans - mfd.ru
Big Picture: Is Alumis Inc in a consolidation phaseWeekly Trend Report & Long-Term Growth Plans - baoquankhu1.vn
Alumis Inc stock hits all-time high at 28.34 USD By Investing.com - Investing.com India
Alumis Inc stock hits all-time high at 28.34 USD - Investing.com Nigeria
Alumis (NASDAQ:ALMS) Sets New 52-Week HighStill a Buy? - MarketBeat
Risk Hedge: Is Alumis Inc gaining market shareJuly 2025 Retail & Technical Pattern Based Buy Signals - baoquankhu1.vn
Huge insider buying now at this insurance giant and 2 biotechs - MSN
Alumis Stock: Key Catalysts on the Horizon for 2026 - AD HOC NEWS
Credit Industriel ET Commercial Sells 140,000 Shares of Alumis Inc. $ALMS - MarketBeat
Why Alumis Inc. stock is trending among retail tradersProduct Launch & Weekly Watchlist for Hot Stocks - mfd.ru
Alumis Inc (ALMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alumis Inc 주식 (ALMS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Foresite Labs, LLC | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Foresite Capital Management VI | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Tananbaum James B. | Director |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| AKKARAJU SRINIVAS | Director |
Dec 05 '25 |
Buy |
9.84 |
186,377 |
1,833,760 |
1,265,253 |
| AKKARAJU SRINIVAS | Director |
Dec 03 '25 |
Buy |
7.75 |
100,000 |
775,000 |
1,012,849 |
| AKKARAJU SRINIVAS | Director |
Dec 02 '25 |
Buy |
7.55 |
96,000 |
724,800 |
912,849 |
| AKKARAJU SRINIVAS | Director |
Dec 04 '25 |
Buy |
8.18 |
66,027 |
540,101 |
1,078,876 |
| AKKARAJU SRINIVAS | Director |
Dec 01 '25 |
Buy |
7.46 |
86,350 |
644,171 |
816,849 |
| AKKARAJU SRINIVAS | Director |
Nov 26 '25 |
Buy |
7.64 |
48,537 |
370,823 |
691,797 |
| AKKARAJU SRINIVAS | Director |
Nov 28 '25 |
Buy |
7.64 |
38,702 |
295,683 |
730,499 |
1.20%
0.06%
자본화:
|
볼륨(24시간):